Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지

Immunogenicity of Recombinant Human Erythropoietin: Clinical Cases, Causes and Assays

  • Heo, Tae-Hwe (Department of Biomedical Laboratory Science, Konyang University) ;
  • Kim, Young-Kwon (Department of Biomedical Laboratory Science, Konyang University) ;
  • Yang, Seung-Ju (Department of Biomedical Laboratory Science, Konyang University) ;
  • Cho, Hyun-Jeong (Department of Biomedical Laboratory Science, Konyang University) ;
  • Kim, Sung-Jo (Department of Biotechnology, Hoseo University)
  • Published : 2009.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Human erythropoietin(EPO) is a glycoprotein that enhances red blood cell production by stimulating proliferation and differentiation of erythroid progenitor cells in the bone marrow. Patients with chronic kidney disease(CKD) suffer from anemia caused by reduced production of EPO in the kidney. Recombinant human EPO protein has been used successfully for the treatment of anemia associated with CKD. Recently, attention has been paid to the development of side effect of EPO, pure red cell aplasia(PRCA), in some patients with CKD. PRCA is a rare disorder of erythropoiesis that leads to a severe anemia due to an almost complete cessation of red blood cell production. EPO-related PRCA is caused by the production of EPO-neutralizing antibodies(Abs) that eliminate the biological activity of EPO as well as endogenous EPO in patients undergoing therapy. Since 1988, almost 200 cases worldwide have been reported with Ab-positive PRCA after receiving EPO therapeutics. The underlying mechanisms of the breaking of immune tolerance to self-EPO have been investigated. Modification of formulation, organic compounds of container closures, and route of administration has been suggested for the possible mechanism of increased immunogenicity of EPO. A number of assays have been used to detect Abs specific to EPO. These assays are generally grouped into two major categories: binding Ab assays and neutralizing Ab assays(bioassays). There are several types of binding Ab assays, including radioimmunoprecipitation assay, enzyme-linked immunosorbent assay, and the BIAcore biosensor assay. In vitro cell-based bioassays have been utilized for the detection of neutralizing Abs. Finally, the recent experience with anti-EPO Abs may have considerable implications for the future development and approval of EPO preparations. Also, considering that millions of patients are being treated with EPO, clinicians need to be aware of signs and consequences of this rare but severe clinical case.

Keywords

References

  1. Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005. 106: 3343-3347.椄돀'—⨀塨?⨀育⨀䄄돐쁖잖⨀쁖잖⨀ꢲ⨀ᤄ덐뢲⨀᠄紀コ⨀
  2. Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005. 20 Suppl 3: iii33-40. https://doi.org/10.1093/ndt/gfh1072
  3. Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005. 67: 2346-2353. https://doi.org/10.1111/j.1523-1755.2005.00340.x
  4. Casadevall N, Cournoyer D, Marsh J, Messner H, Pallister C, Parker-Williams J, Rossert J. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004. 73: 389-396. https://doi.org/10.1111/j.1600-0609.2004.00348.x
  5. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med. 1996. 334: 630-633. https://doi.org/10.1056/NEJM199603073341004
  6. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin- Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002. 346: 469-475. https://doi.org/10.1056/NEJMoa011931
  7. Datamonitor. Therapeutic Proteins: Strategic Market Analysis and Forecasts to 2010: Market Research.com 2002. p. 252.
  8. Eckardt KU, Casadevall N. Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol Dial Transplant 2003. 18: 865-869. https://doi.org/10.1093/ndt/gfg182
  9. Gribben JG, Devereux S, Thomas NS, Keim M, Jones HM, Goldstone AH, Linch DC. Development of antibodies to unprotected glycosylation sites on recombinant human GMCSF. Lancet 1990. 335: 434-437. https://doi.org/10.1016/0140-6736(90)90665-R
  10. Johnson & Johnson Pharmaceutical Research & Development LLC. Summary of PRCA Case Reports. Available at: http:// www.jnjpharmarnd.com/company/news.html, 2008.
  11. Krantz SB. Pure red-cell aplasia. N Engl J Med. 1974. 291: 345 -350. https://doi.org/10.1056/NEJM197408152910707
  12. Ottesen JL, Nilsson P, Jami J, Weilguny D, Duhrkop M, Bucchini D, Havelund S, Fogh JM. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 1994. 37: 1178-1185. https://doi.org/10.1007/BF00399790
  13. Palleroni AV, Aglione A, Labow M, Brunda MJ, Pestka S, Sinigaglia F, Garotta G, Alsenz J, Braun A. Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a. J Interferon Cytokine Res. 1997. 17 Suppl 1: S23-27.
  14. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002. 24: 1720 -1740; discussion 1719. https://doi.org/10.1016/S0149-2918(02)80075-3
  15. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2003. 18: 1257-1259. https://doi.org/10.1093/ndt/gfg164
  16. Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol. 2006. 24: 613-614. https://doi.org/10.1038/nbt0606-613
  17. Stewart TA, Hollingshead PG, Pitts SL, Chang R, Martin LE, Oakley H. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med. 1989. 6: 275-281.
  18. Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract. 2004. 96: c88-95. https://doi.org/10.1159/000076746
  19. Thorpe R, Swanson SJ. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant 2005. 20 Suppl 4: iv16-22. https://doi.org/10.1093/ndt/gfh1086
  20. Thorpe R, Swanson SJ. Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin Diagn Lab Immunol. 2005. 12: 28-39
  21. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004. 363: 1768 -1771. https://doi.org/10.1016/S0140-6736(04)16302-2
  22. Yang J, Joo KW, Kim YS, Ahn C, Han JS, Kim S, Lee JS. Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies. J Nephrol. 2005. 18: 102-105.